The growing deaths from non-communicable diseases attributable to sugar-sweetened beverages among young and middle-aged adults: Analysis and projection based on Global Burden of Disease Study 2021
Diabetes & Metabolic Syndrome: Clinical Research & Reviews · 2025-08 · 19 (8) · 103296
DOI: 10.1016/j.dsx.2025.103296 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2025-08. Verfasst von Chang Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Noncommunicable Diseases, Global Burden of Disease, Sugar-Sweetened Beverages. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Beijing Municipal Health Commission.
Abstract (Originalsprache)
INTRODUCTION: Despite rising global health concerns about sugar-sweetened beverages (SSBs), their long-term impact on non-communicable disease (NCD) death across demographic groups and socioeconomic contexts remains poorly understood. METHODS: We analyzed SSB-attributable NCD death trends using the Global Burden of Disease (GBD) Study 2021 data from 204 countries (1990-2021). Time trends in death were expressed as average annual percent change (AAPC), stratified by age and socio-demographic index (SDI). Future trends through 2051 were projected using Bayesian age-period-cohort modeling. RESULTS: SSB-attributable deaths increased from 27,286 (95 % UI: 11,099-42,134) in 1990 to 74,657 (95 % UI: 33,724-115,575) in 2021. The age-standardized death rate rose from 0.784 to 0.889 per 100,000 (AAPC: 0.460 %, 95 % CI: 0.326-0.594). Young and middle-aged adults exhibited a rapid increase in deaths, with an AAPC of 1.250 % (95 % CI: 1.070-1.420) observed in the 25-29 age group, particularly due to chronic kidney disease (AAPC: 2.779 %, 95 % CI: 2.626-2.931). Low-middle SDI regions experienced the most dramatic increase (AAPC: 2.569 %, 95 % CI: 2.453-2.684). CONCLUSION: Our findings reveal an alarming rise in SSB-attributable NCD deaths, particularly affecting young adults and resource-limited regions. This growing health equity challenge requires urgent policy interventions and prevention strategies to protect vulnerable populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
- Beijing Diabetes Institute, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
- Department of Mathematics, School of Biomedical Engineering, Capital Medical University, Beijing, China.
- Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, China. Electronic address: xinz@medmail.com.cn.
Förderung
- Beijing Municipal Health Commission
Zitieren
APA
Liu, C., Wang, H., Hua, L., & Xin, Z. (2025). The growing deaths from non-communicable diseases attributable to sugar-sweetened beverages among young and middle-aged adults: Analysis and projection based on Global Burden of Disease Study 2021. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 19(8), 103296. https://doi.org/10.1016/j.dsx.2025.103296
Vancouver
Liu C, Wang H, Hua L, Xin Z. The growing deaths from non-communicable diseases attributable to sugar-sweetened beverages among young and middle-aged adults: Analysis and projection based on Global Burden of Disease Study 2021. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2025;19(8):103296. doi:10.1016/j.dsx.2025.103296
BibTeX
@article{Liu2025,
author = {Liu, Chang and Wang, Hao and Hua, Lin and Xin, Zhong},
title = {The growing deaths from non-communicable diseases attributable to sugar-sweetened beverages among young and middle-aged adults: Analysis and projection based on Global Burden of Disease Study 2021},
journal = {Diabetes & Metabolic Syndrome: Clinical Research & Reviews},
year = {2025},
volume = {19},
number = {8},
pages = {103296},
doi = {10.1016/j.dsx.2025.103296}
}
EUVIMED